Struggling to find Levemir at your pharmacy? Learn why this long-acting insulin is so hard to find in 2026 and what you can do about it.
If you or someone you love depends on Levemir (Insulin Detemir) to manage diabetes, you may have already experienced the frustration of showing up at the pharmacy only to hear, "We don't have it in stock." You're not imagining things — Levemir has become increasingly difficult to find across the United States, and the situation has only gotten worse heading into 2026.
In this article, we'll break down exactly what's happening with Levemir, why it's so hard to find, and what steps you can take right now to make sure you don't go without your insulin.
Levemir is a brand-name, long-acting insulin made by Novo Nordisk. Its generic name is Insulin Detemir. It's used to control blood sugar levels in adults and children (ages 2 and older) with type 1 diabetes and adults with type 2 diabetes.
Levemir works by slowly releasing insulin over a period of up to 24 hours, which helps keep blood sugar levels steady between meals and overnight. It's typically injected once or twice a day under the skin using a prefilled FlexTouch pen or a vial and syringe.
For a deeper look at how this medication works, check out our guide on how Levemir works.
There are several reasons why Levemir has become scarce. Here are the main factors driving the shortage:
The biggest reason Levemir is hard to find is that its manufacturer, Novo Nordisk, has announced that it is discontinuing production of the drug. This isn't a temporary manufacturing hiccup — the company is phasing out Levemir entirely. Production has been winding down since late 2024, and supplies in the U.S. have been shrinking steadily throughout 2025 and into 2026.
In the UK, remaining supplies are expected to run out by December 2026. The situation is similar in the U.S., where available inventory continues to decline.
Unlike some other long-acting insulins — such as Insulin Glargine, which has biosimilars like Basaglar and Semglee — there is currently no generic or biosimilar version of Insulin Detemir. This means that once Novo Nordisk stops making Levemir, there is no alternative manufacturer to pick up the slack.
As the discontinuation has progressed, many insurance companies and Medicare Part D plans have moved Levemir to higher formulary tiers or removed it from their covered drug lists entirely. This has created a double problem: even when pharmacies do have Levemir, some patients find that their insurance no longer covers it, making it unaffordable.
Even when some Levemir inventory remains in the distribution pipeline, it's not evenly distributed. Large chain pharmacies may run out quickly, while smaller independent pharmacies might still have stock — or vice versa. This unpredictability makes it hard for patients to know where to look.
The good news is that you have options. Here's what you can do right now:
Medfinder lets you search for Levemir availability at pharmacies near you in real time. Instead of calling pharmacy after pharmacy, you can check stock from your phone or computer in seconds. This is the fastest way to find out which pharmacies currently have Levemir on their shelves.
Independent and compounding pharmacies sometimes have better access to medications that are in short supply at larger chains. Don't overlook these smaller pharmacies — they may be your best bet. For more tips, read our article on how to find Levemir in stock near you.
If Levemir is truly unavailable in your area, your doctor can help you switch to an alternative long-acting insulin. Options include Insulin Glargine (Lantus, Basaglar, or Semglee), Insulin Degludec (Tresiba), or NPH Insulin (Humulin N, Novolin N). Each of these works a little differently, so your doctor will help find the best fit. We cover this in more detail in our post on alternatives to Levemir.
If your pharmacy does have Levemir in stock, ask your doctor if they can write your prescription for a 90-day supply instead of 30 days. This can help you build a small buffer while the drug is still available.
If cost is a barrier, Novo Nordisk's patient assistance program through NovoCare may still be able to help qualifying patients get insulin at no cost. You can also check our guide to saving money on Levemir for more options.
Levemir's growing scarcity in 2026 is a real and serious issue for the millions of people who depend on it. The manufacturer's decision to discontinue the drug, combined with the lack of a biosimilar, has created a challenging situation for patients and providers alike.
The most important thing you can do is plan ahead. Use tools like Medfinder to track availability, talk to your doctor about a transition plan to an alternative insulin, and don't wait until your last pen or vial to start looking for your next refill.
You deserve consistent access to the medication that keeps you healthy. We're here to help you find it.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
